Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19558
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChao, Michael-
dc.contributor.authorLim Joon, Daryl-
dc.contributor.authorKhoo, Vincent-
dc.contributor.authorLawrentschuk, Nathan-
dc.contributor.authorHo, Huong-
dc.contributor.authorSpencer, Sandra-
dc.contributor.authorChan, Yee-
dc.contributor.authorTan, Alwin-
dc.contributor.authorPham, Trung-
dc.contributor.authorSengupta, Shomik-
dc.contributor.authorMcMillan, Kevin-
dc.contributor.authorLiu, Madalena-
dc.contributor.authorKoufogiannis, George-
dc.contributor.authorCham, Chee Wee-
dc.contributor.authorForoudi, Farshad-
dc.contributor.authorBolton, Damien M-
dc.date2018-09-24-
dc.date.accessioned2018-10-11T02:50:05Z-
dc.date.available2018-10-11T02:50:05Z-
dc.date.issued2019-06-
dc.identifier.citationWorld Journal of Urology 2019; 37(6): 1111-1116en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19558-
dc.description.abstractThe purpose of this study was to determine whether the degree of prostate to rectal separation using a hydrogel spacer (HS) and its effect on decreasing rectal dose can be reproduced in the community setting. Thirty one patients with cT1-3aN0M0 prostate adenocarcinoma receiving radical radiotherapy to 78 Gy were recruited to the study. The primary endpoint was the proportion of patients achieving at least 25% reduction in volume of rectum receiving 70 Gy (rV70). Other endpoints included degree of prostate to rectum separation, HS insertion-related adverse events and the proportion of patients with grade 1 or worse acute or late gastrointestinal (GI) and genitourinary (GU) toxicity. All patients had successful insertion of their HS with no peri-operative toxicity. The mean prostate-rectal separation achieved was 10.5 mm. Twenty nine (93.5%) patients achieved a reduction in rV70 of at least 25%. Acute grade 1 GI toxicity was reported in 3 patients. All symptoms had resolved by 3 months post RT. Late grade 1 GI toxicity was reported in one patient (3.2%) with bowel frequency occurring at 6 months and resolving by 12 months post RT. There was no grade 2 or 3 acute or late GI toxicity seen. In conclusion, this study illustrates that the application and benefits of HS on reducing GI rectal dose endpoints and toxicities during prostate cancer RT can be reliably replicated in a community setting similar to centres participating in the randomised trial under high quality assurance trial monitoring.en_US
dc.language.isoeng-
dc.subjectHydrogel spaceren_US
dc.subjectProstate canceren_US
dc.subjectRadiotherapyen_US
dc.titleThe use of hydrogel spacer in men undergoing high-dose prostate cancer radiotherapy: results of a prospective phase 2 clinical trial.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleWorld Journal of Urologyen_US
dc.identifier.affiliationThe Valley Private Hospital, Mulgrave, Australiaen_US
dc.identifier.affiliationThe Box Hill Hospital, Box Hill, Australiaen_US
dc.identifier.affiliationGenesis Cancer Care Victoria, 36 Mt Dandenong Road, Ringwood East, VIC, 3135, Australiaen_US
dc.identifier.affiliationAustin Healthen_US
dc.identifier.affiliationUniversity of Melbourne, Melbourne, Australiaen_US
dc.identifier.affiliationMonash University, Melbourne, Australiaen_US
dc.identifier.affiliationRoyal Marsden Hospital, London, UKen_US
dc.identifier.affiliationThe Bays Hospital, Mornington, Australiaen_US
dc.identifier.affiliationRingwood Private Hospital, Ringwood East, Australiaen_US
dc.identifier.doi10.1007/s00345-018-2502-5en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-5145-6783en_US
dc.identifier.orcid0000-0002-3497-3746en_US
dc.identifier.orcid0000-0001-8553-5618en_US
dc.identifier.orcid0000-0003-3357-1216en_US
dc.identifier.orcid0000-0001-8387-0965en_US
dc.identifier.pubmedid30251049-
dc.type.austinJournal Article-
local.name.researcherBolton, Damien M
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptRadiation Oncology-
crisitem.author.deptRadiation Oncology-
crisitem.author.deptUrology-
crisitem.author.deptUrology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptRadiation Oncology-
crisitem.author.deptUrology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

72
checked on Dec 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.